JP2013518128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518128A5 JP2013518128A5 JP2012551318A JP2012551318A JP2013518128A5 JP 2013518128 A5 JP2013518128 A5 JP 2013518128A5 JP 2012551318 A JP2012551318 A JP 2012551318A JP 2012551318 A JP2012551318 A JP 2012551318A JP 2013518128 A5 JP2013518128 A5 JP 2013518128A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- rap
- agent
- item
- peptide complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 239000000863 peptide conjugate Substances 0.000 claims description 13
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims description 12
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 108010071471 glutamyl-leucyl-lysyl-valyl-leucyl-methionyl-glutamyl-lysyl-glutamyl-leucine Proteins 0.000 claims description 10
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 239000002254 cytotoxic agent Substances 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 4
- 239000000412 dendrimer Substances 0.000 claims description 4
- 229920000736 dendritic polymer Polymers 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- QPXXQIKORIGFSB-UTINFBMNSA-N (3r,4r,5s,6s)-1-butyl-4,5,6-trihydroxyazepane-3-carboxylic acid Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)C1 QPXXQIKORIGFSB-UTINFBMNSA-N 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 2
- AFRPVDHJWCJLNM-UHFFFAOYSA-N beta-1-C-ethyl-deoxymannojirimycin Natural products CCC1NC(CO)C(O)C(O)C1O AFRPVDHJWCJLNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 231100000753 hepatic injury Toxicity 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 239000000562 conjugate Substances 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- -1 radioisotopes Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29917710P | 2010-01-28 | 2010-01-28 | |
| US61/299,177 | 2010-01-28 | ||
| PCT/US2011/022917 WO2011094536A1 (en) | 2010-01-28 | 2011-01-28 | Method for treating liver disorders with receptor associated protein ( irp) peptide-fucosidase inhibitor conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016043181A Division JP2016145231A (ja) | 2010-01-28 | 2016-03-07 | 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518128A JP2013518128A (ja) | 2013-05-20 |
| JP2013518128A5 true JP2013518128A5 (https=) | 2014-02-20 |
| JP6170675B2 JP6170675B2 (ja) | 2017-07-26 |
Family
ID=44319804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551318A Expired - Fee Related JP6170675B2 (ja) | 2010-01-28 | 2011-01-28 | 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 |
| JP2016043181A Pending JP2016145231A (ja) | 2010-01-28 | 2016-03-07 | 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016043181A Pending JP2016145231A (ja) | 2010-01-28 | 2016-03-07 | 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110189084A1 (https=) |
| EP (1) | EP2528613B1 (https=) |
| JP (2) | JP6170675B2 (https=) |
| KR (1) | KR101784539B1 (https=) |
| CN (1) | CN102905716B (https=) |
| AU (1) | AU2011210756B2 (https=) |
| CA (1) | CA2788175A1 (https=) |
| ES (1) | ES2555555T3 (https=) |
| TW (1) | TWI558397B (https=) |
| WO (1) | WO2011094536A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| RU2474423C1 (ru) * | 2011-12-20 | 2013-02-10 | Федеральное государственное бюджетное учреждение науки Институт общей физики им. А.М. Прохорова Российской академии наук (ИОФ РАН) | Способ лечения метастазов печени |
| WO2014160088A2 (en) * | 2013-03-14 | 2014-10-02 | Rhode Island Hospital, A Lifespan-Partner | Treating hepatitis b virus infections |
| CN107848970B (zh) * | 2015-07-30 | 2021-07-06 | 地平线孤儿病有限责任公司 | 岩藻糖苷酶抑制剂 |
| WO2020229968A1 (en) * | 2019-05-10 | 2020-11-19 | Alectos Therapeutics Inc. | Non-lysosomal glucosylceramidase inhibitors and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US5186941A (en) | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
| US5153325A (en) | 1989-06-27 | 1992-10-06 | Monsanto Company | Fucosidase inhibitor |
| US5100797A (en) | 1989-06-27 | 1992-03-31 | Monsanto Company | Fucosidase inhibitors |
| US5096909A (en) | 1989-06-27 | 1992-03-17 | Monsanto Company | Fucosidase inhibitor |
| US5017704A (en) | 1989-06-27 | 1991-05-21 | Monsanto Company | Fucosidase inhibitor |
| US5240707A (en) | 1990-04-12 | 1993-08-31 | Merrell Dow Pharma | Alpha-mannosidase and fucosidase inhibitors |
| CA2040058C (en) * | 1990-04-12 | 2001-10-23 | Robert A. Farr | Alpha-mannosidase and fucosidase inhibitors |
| US5474766A (en) | 1992-12-18 | 1995-12-12 | Washington University | Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator |
| TW492882B (en) * | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| US6589954B1 (en) * | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU1840101A (en) * | 1999-08-10 | 2001-03-05 | Chancellor, Masters And Scholars Of The University Of Oxford, The | Long chain n-alkyl compounds and oxo-derivatives thereof |
| US6261595B1 (en) * | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| EP1411952B1 (en) * | 2001-06-29 | 2009-04-22 | Glykos Finland Oy | Use of at least one glycoinhibitor substance against infectious diseases |
| US6852842B2 (en) | 2002-08-26 | 2005-02-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for functional kidney imaging using small dendrimer contrast agents |
| CA2525236C (en) * | 2003-06-20 | 2015-03-24 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US20060198819A1 (en) | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| CN101283046A (zh) | 2005-07-18 | 2008-10-08 | 斯克里普斯研究学院 | 制备两亲性树枝状聚合物的方法 |
| WO2008011617A2 (en) | 2006-07-21 | 2008-01-24 | The Regents Of The University Of California | Shallow-trench-isolation (sti)-bounded single-photon avalanche photodetectors |
| MX2009002893A (es) | 2006-09-18 | 2009-07-10 | Raptor Pharmaceutical Inc | Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap). |
| US20080116171A1 (en) * | 2006-11-22 | 2008-05-22 | Clarkson University | Method For The Preferential Polishing Of Silicon Nitride Versus Silicon Oxide |
| KR20100015786A (ko) * | 2007-03-21 | 2010-02-12 | 랩터 파마슈티컬 인코포레이티드 | 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드 |
| US8236753B2 (en) * | 2007-12-10 | 2012-08-07 | The Brigham And Women's Hospital, Inc. | RAP variants for drug delivery and methods of use thereof |
| WO2009151687A2 (en) * | 2008-03-12 | 2009-12-17 | The Regents Of The University Of Michigan | Dendrimer conjugates |
-
2011
- 2011-01-28 US US13/016,135 patent/US20110189084A1/en not_active Abandoned
- 2011-01-28 TW TW100103531A patent/TWI558397B/zh not_active IP Right Cessation
- 2011-01-28 CA CA2788175A patent/CA2788175A1/en not_active Abandoned
- 2011-01-28 JP JP2012551318A patent/JP6170675B2/ja not_active Expired - Fee Related
- 2011-01-28 WO PCT/US2011/022917 patent/WO2011094536A1/en not_active Ceased
- 2011-01-28 EP EP11737725.9A patent/EP2528613B1/en not_active Not-in-force
- 2011-01-28 AU AU2011210756A patent/AU2011210756B2/en not_active Ceased
- 2011-01-28 CN CN201180016788.XA patent/CN102905716B/zh not_active Expired - Fee Related
- 2011-01-28 ES ES11737725.9T patent/ES2555555T3/es active Active
- 2011-01-28 KR KR1020127022072A patent/KR101784539B1/ko not_active Expired - Fee Related
-
2016
- 2016-03-07 JP JP2016043181A patent/JP2016145231A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1340603C (en) | Tri-aza macrocycles and metal complexes thereof | |
| JP2013518128A5 (https=) | ||
| Moreno et al. | Reduction of advanced liver fibrosis by short‐term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats | |
| JP2008195715A5 (https=) | ||
| JP2010502629A5 (https=) | ||
| JP2018506550A5 (https=) | ||
| WO2020142583A1 (en) | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates | |
| JP3054346B2 (ja) | ペプチド類 | |
| TWI549690B (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| JP2012102122A5 (https=) | ||
| TW201026335A (en) | Selective seprase inhibitors | |
| JP2020520382A5 (https=) | ||
| JP2013518086A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2011132258A (ja) | 改良放射性金属錯体組成物 | |
| JP2011526917A5 (https=) | ||
| JP2008515889A5 (https=) | ||
| CA2949365A1 (en) | One-step labeling of antibodies to high specific activity with actinium-225 | |
| JP2026026133A (ja) | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 | |
| US20030023050A1 (en) | Actinium-225 complexes and conjugates for targeted radiotherapy | |
| JP2024016209A5 (https=) | ||
| Colleoni et al. | A phase II study of mitoxantrone combined with beta‐interferon in unresectable hepatocellular carcinoma | |
| JP2021501800A5 (https=) | ||
| KR20080099279A (ko) | 이관능성 레조르시놀, 티오레조르시놀, 및 디티오레조르시놀 유도체 금속 킬레이팅 컨쥬게이트 | |
| AU2018347406B2 (en) | Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy |